JPMorgan Chase & Co. lessened its position in Veeva Systems Inc. (NYSE:VEEV – Free Report) by 27.5% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 2,521,946 shares of the technology company’s stock after selling 954,312 shares during the quarter. JPMorgan Chase & Co.’s holdings in Veeva Systems were worth $562,974,000 as of its most recent filing with the Securities & Exchange Commission.
Several other hedge funds also recently made changes to their positions in VEEV. Vanguard Group Inc. grew its stake in Veeva Systems by 3.1% in the third quarter. Vanguard Group Inc. now owns 15,429,231 shares of the technology company’s stock worth $4,596,522,000 after purchasing an additional 457,806 shares during the period. Alliancebernstein L.P. lifted its position in Veeva Systems by 4.1% during the third quarter. Alliancebernstein L.P. now owns 5,941,631 shares of the technology company’s stock valued at $1,770,071,000 after buying an additional 235,983 shares during the period. Principal Financial Group Inc. lifted its position in Veeva Systems by 0.6% during the fourth quarter. Principal Financial Group Inc. now owns 3,870,293 shares of the technology company’s stock valued at $863,978,000 after buying an additional 23,416 shares during the period. State Street Corp boosted its holdings in shares of Veeva Systems by 2.2% during the 3rd quarter. State Street Corp now owns 3,503,730 shares of the technology company’s stock valued at $1,043,796,000 after buying an additional 76,397 shares in the last quarter. Finally, Geode Capital Management LLC grew its position in shares of Veeva Systems by 0.7% in the 4th quarter. Geode Capital Management LLC now owns 3,172,716 shares of the technology company’s stock worth $706,442,000 after buying an additional 23,117 shares during the period. 88.20% of the stock is currently owned by institutional investors.
Key Veeva Systems News
Here are the key news stories impacting Veeva Systems this week:
- Positive Sentiment: UCB is unifying global safety operations on Veeva Safety Suite, a sign of continued customer adoption for Veeva’s regulated-industry software platform. UCB Unifies Global Pharmacovigilance Operations with Veeva Safety Suite
- Positive Sentiment: Analysts highlighted Veeva’s strong Q1, growing Vault CRM migrations, and AI expansion as reasons the stock may deserve a place in portfolios. Reasons to Add Veeva Systems Stock to Your Portfolio for Now
- Positive Sentiment: Management’s product push, including Falcon and Vault AI, is improving workflow automation across life sciences and supporting the long-term growth narrative. Veeva’s Falcon and Vault AI: When Could AI Become a Revenue Driver?
- Neutral Sentiment: Recent commentary from Veeva’s earnings call pointed to broad-based customer demand and stronger execution, but also said AI revenue is not expected to be a major contributor in fiscal 2027. The 5 Most Interesting Analyst Questions From Veeva Systems’s Q1 Earnings Call
- Negative Sentiment: Investors are also weighing concerns about saturation in the life sciences CRM market and the fact that AI monetization may take longer to show up in results. Reasons to Add Veeva Systems Stock to Your Portfolio for Now
Insider Buying and Selling
Wall Street Analyst Weigh In
VEEV has been the subject of several research reports. Zacks Research lowered shares of Veeva Systems from a “strong-buy” rating to a “hold” rating in a research note on Thursday, May 14th. Mizuho dropped their price objective on shares of Veeva Systems from $295.00 to $270.00 and set an “outperform” rating on the stock in a research note on Thursday, June 4th. The Goldman Sachs Group cut their price objective on shares of Veeva Systems from $190.00 to $165.00 and set a “sell” rating on the stock in a report on Thursday, June 4th. Wells Fargo & Company raised their target price on shares of Veeva Systems from $317.00 to $320.00 and gave the company an “overweight” rating in a research note on Thursday, June 4th. Finally, BTIG Research reiterated a “buy” rating and set a $340.00 target price on shares of Veeva Systems in a report on Thursday, June 4th. Eighteen equities research analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Veeva Systems has an average rating of “Moderate Buy” and an average price target of $250.96.
Check Out Our Latest Stock Analysis on Veeva Systems
Veeva Systems Stock Down 2.3%
Shares of NYSE VEEV opened at $163.82 on Thursday. The firm has a market cap of $26.76 billion, a P/E ratio of 29.20, a PEG ratio of 0.73 and a beta of 0.95. Veeva Systems Inc. has a twelve month low of $148.05 and a twelve month high of $310.50. The company has a 50 day moving average of $165.61 and a 200 day moving average of $192.92.
Veeva Systems (NYSE:VEEV – Get Free Report) last issued its earnings results on Wednesday, June 3rd. The technology company reported $2.24 EPS for the quarter, beating the consensus estimate of $2.14 by $0.10. Veeva Systems had a return on equity of 13.72% and a net margin of 28.37%.The business had revenue of $882.95 million for the quarter, compared to the consensus estimate of $857.73 million. During the same period last year, the business posted $1.97 EPS. The company’s revenue was up 16.3% compared to the same quarter last year. Veeva Systems has set its FY 2027 guidance at 9.050-9.050 EPS and its Q2 2027 guidance at 2.210-2.220 EPS. As a group, equities analysts expect that Veeva Systems Inc. will post 6.55 earnings per share for the current fiscal year.
Veeva Systems Profile
Veeva Systems (NYSE: VEEV) is a cloud software company that develops industry-specific applications and data solutions for the global life sciences sector. Founded in 2007 and headquartered in Pleasanton, California, Veeva focuses on helping pharmaceutical, biotechnology, medical device and consumer health companies manage regulated content, clinical and regulatory processes, quality systems, and commercial operations in a compliant, cloud-native environment. The company completed its initial public offering in 2013 and has since expanded its product suite and international footprint.
Veeva’s product portfolio centers on its Vault platform and related application suites, which provide content and data management, clinical trial and regulatory workflows, quality management, and structured commercial capabilities such as customer relationship management and promotional content management.
Featured Articles
- Five stocks we like better than Veeva Systems
- Everpure: AI Storage Uncertainty Overshadows Breakneck Growth
- This Tech ETF Is Beating QQQ—and Canada May Be Part of the Reason
- Intel Is the Market’s Most Mispriced AI Hedge
- The Biggest Opportunity From SpaceX’s IPO May Surprise You
Want to see what other hedge funds are holding VEEV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Veeva Systems Inc. (NYSE:VEEV – Free Report).
Receive News & Ratings for Veeva Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veeva Systems and related companies with MarketBeat.com's FREE daily email newsletter.
